Title Credit Type Event date Cost
New Hope on the Horizon - Advances in the Diagnosis and Treatment of Idiopathic Hypersomnia
    • 1.75 ACPE Pharmacy
    • 1.75 AMA PRA Category 1 Credit™
    • 1.75 ANCC
    • 1.75 Participation
 Enduring $0.00
18th Annual CMHC On Demand
    • 19.25 CDE
    • 19.25 ACPE Pharmacy
    • 19.25 AMA PRA Category 1 Credit™
    • 19.25 ANCC
    • 19.25 Participation
 Enduring $0.00
Clinical Brief: The Burden of Resistant Hypertension in Women - Novel and Emerging Approaches to Improve Outcomes
    • 0.75 ACPE Pharmacy
    • 0.75 AMA PRA Category 1 Credit™
    • 0.75 ANCC
    • 0.75 Participation
 Enduring $0.00
Tackling the Disproportionate Burden of Resistant Hypertension in Black Adults
    • 1.00 CDE
    • 1.00 ACPE Pharmacy
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 ANCC
    • 1.00 Participation
 Enduring $0.00
Webcast: Addressing and Treating Iron Deficiency to Improve Symptoms and Outcomes in Patients with Heart Failure
    • 1.00 ACPE Pharmacy
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 ANCC
    • 1.00 Participation
 Enduring $0.00
Challenges and Solutions in Lipid-Lowering Therapy in Women: From Gaps to Practice-Changing Advances
    • 1.50 ACPE Pharmacy
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 ANCC
    • 1.50 Participation
 Enduring $0.00
Escape Room Experience: Individualizing Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes
    • 1.00 ACPE Pharmacy
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 ANCC
    • 1.00 Participation
 Enduring $0.00
Breaking Through Inertia: How to Initiate and Maintain Insulin Therapy in Patients with Type 2 Diabetes
    • 1.50 AAFP
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Participation
 Enduring $0.00
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
    • 0.75 ACPE Pharmacy
    • 0.75 AMA PRA Category 1 Credit™
    • 0.75 ANCC
    • 0.75 Participation
 Enduring $0.00
Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk: A Paradigm Shift
    • 1.50 CDE
    • 1.50 ACPE Pharmacy
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 ANCC
    • 1.50 Participation
 Enduring $0.00
Ace the Case Challenge Series: Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk
    • 0.75 ACPE Pharmacy
    • 0.75 AMA PRA Category 1 Credit™
    • 0.75 ANCC
    • 0.75 Participation
 Enduring $0.00
Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD
    • 1.50 CDE
    • 1.50 ACPE Pharmacy
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 ANCC
    • 1.50 Participation
 Enduring $0.00
Ace the Case Challenge Series: The Intersection of MASH and Cardiometabolic Risk
    • 0.50 CDE
    • 0.50 ACPE Pharmacy
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 ANCC
    • 0.50 Participation
 Enduring $0.00
The Burden of Resistant Hypertension in Women: Novel and Emerging Approaches to Improve Outcomes
    • 0.50 ACPE Pharmacy
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 ANCC
    • 0.50 Participation
 Enduring $0.00
The Risk Stratification and Treatment of Chronic Kidney Disease in Women: Uncovering and Addressing Disparities to Improve Outcomes
    • 1.00 ACPE Pharmacy
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 ANCC
    • 1.00 Participation
 Enduring $0.00

Pages